Evidence and analysis
Research evidence pack
Source-backed valuation visuals
2. Company Fundamentals
2.1 Competitiveness
| Metric | Value |
|---|---|
| Free Float | 0.49B |
| Short Int % Utilisation | 14.08% |
2.2 Growth
| Metric | Value |
|---|---|
| EV/EBITDA | -42.45 |
2.3 Management
| Role | Metric |
|---|---|
| Consensus Rating | N/A |
2.4 Return
| Metric | Value |
|---|---|
| Expected Return (Ann.)* | 42.58% |
| Risk / Std Dev (Ann.)* | 79.12% |
| 1-Year Price Return* | 4.47% |
Latest Market Data (as of 2026-08-14, US Eastern time):
| Metric | Value |
|---|---|
| Last Price | $11.21 |
| 52-Week Range | $8.91 – $20.34 |
| Observation Count | 251 trading days |
The return and risk statistics use daily adjusted closes from the retrieved one-year series and annualise daily moments using 252 trading days. The last price is the latest regular-market price reported for the stated date. Source: Yahoo Finance market data.
DuPont Model Analysis
The DuPont model decomposes return on equity (ROE) into three operating and capital-structure drivers:
ROE = Net Margin × Asset Turnover × Equity Multiplier
The comparison uses the latest two comparable annual periods available for the issuer, with reported statement amounts shown in US$. Revenue and net income are income-statement flows; total assets and shareholders’ equity are year-end balance-sheet figures. This is a simplified year-end-balance DuPont comparison rather than an average-balance ROE calculation.
| DuPont component | Calculation | FY2025 | FY2024 |
|---|---|---|---|
| Revenue | Reported revenue | $66.84M | $224K |
| Net income | Reported net income | $-87.66M | $-29.22M |
| Total assets | Year-end reported balance | $1.11B | $889.83M |
| Shareholders’ equity | Year-end reported balance | $983.90M | $778.11M |
| Net margin | Net income ÷ revenue | -131.15% | -13045.09% |
| Asset turnover | Revenue ÷ total assets | 0.0603x | 0.0003x |
| Equity multiplier | Total assets ÷ shareholders’ equity | 1.1258x | 1.1436x |
| ROE | Net margin × asset turnover × equity multiplier | -8.91% | -3.76% |
Source: Yahoo Finance annual statements. Values are based on the two latest comparable annual periods returned by the source; fiscal period labels use the statement period-end year.
2.5 FCFF DCF Valuation
FCFF DCF exception: Reported operating inputs do not support a stable FCFF DCF. This post deliberately does not publish a mechanical enterprise value or implied per-share value on an unsuitable basis.
| Available valuation input | Value |
|---|---|
| Last market price | $10.77 |
| Market capitalisation | $5.28B |
| Revenue | $66.84M |
| EBIT | -$88.99M |
| Reported free cash flow | -$70.15M |
| FCF yield | -1.33% |
| Net debt / EBITDA | 1.74x |
2.6 Investor-Style Research Screen
| Educational screen | Result |
|---|---|
| Buffett-inspired cash-quality checks | not rated — FCFF DCF suitability or data-integrity condition not met |
| Lynch-inspired balance-and-growth checks | not rated — FCFF DCF suitability or data-integrity condition not met |
Data lineage: Yahoo Finance public market and reported-statement data; retrieval timestamp: 2026-08-18 17:52:31.901031 UTC; latest reported fiscal period: 2025-07-31 00:00:00. Financial institutions and REITs require sector-specific methods rather than a mechanical FCFF DCF. This is research and analysis only, not personalized financial advice.
2.7 Quantitative Factor Diagnostics
Model basis: Daily issuer USD excess returns are regressed in-sample using ordinary least squares on matching regional Fama–French factors. FF3 estimates market, size, and value loadings; FF5 adds profitability and investment. Coefficients are descriptive historical exposures, not predictions.
| Estimation input | Value |
|---|---|
| Regional factor set | US |
| Factor-return currency | USD |
| Issuer-return basis | USD adjusted total return |
| Estimation window | 2025-08-19 to 2026-06-30 |
| Aligned daily observations | 217 |
| Minimum observation requirement | 120 |
| Currency conversion for HK listings | not required |
Fama–French Three-Factor and Five-Factor Results
| Diagnostic | FF3 | FF5 |
|---|---|---|
| Annualised alpha | 3.13% | -34.93% |
| Adjusted R² | 0.24 | 0.30 |
| Annualised residual volatility | 71.21% | 68.21% |
| Factor loading (t-statistic) | FF3 | FF5 |
|---|---|---|
| Market excess return (Mkt-RF) | 2.30 (5.50) | 1.32 (2.85) |
| Size (SMB) | 1.39 (2.45) | 1.34 (2.29) |
| Value (HML) | -1.10 (-2.26) | -0.12 (-0.20) |
| Profitability (RMW) | NM | -1.71 (-3.48) |
| Investment (CMA) | NM | -1.53 (-1.80) |